Two specific, sensitive, and precise stabilityindicating chromatographic methods have been developed for the determination of triamcinolone acetonide (TMC) and its coformulated drug, econazole nitrate (ECZ), in the presence of TMC impurities and degradation products. The first method was based on HPTLC-spectrodensitometry in which resolution and quantitation was achieved by using silica gel 60 F 254 HPTLC plates and an ethyl acetate-tetrahydrofuran-ammonia mobile phase (10.0 + 7.0 + 0.1, v/v/v). The second method was a reversed-phase HPLC method in which separation was achieved using an acetonitrile-methanol-0.05 M potassium dihydrogen phosphate mobile phase, pH 3.0 (25.0 + 15.0 + 60.0, v/v/v). In both methods, the separated components were detected at 225 nm. Validation of both methods was conducted in compliance with International Conference on Harmonization (ICH) guidelines, and system suitability was confirmed. The linearity ranges were 0.20-28.00 and 0.50-55.00 µg/band for TMC and ECZ by HPTLC, whereas for HPLC, the range was 0.05-30.00 and 1.00-40.00 µg/mL for both drugs, respectively. The methods were successfully applied for the analysis of a pharmaceutical formulation and were compared with the reported method with no significant difference.
T riamcinolone acetonide (TMC) is chemically designated as pregna-1,4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene) bis(oxy)]-, (11b,16a) (1; Figure 1 ). It is a topical corticosteroid belongs to the synthetic steroid class of drugs and is used as an anti-inflammatory and antipruritic agent either alone or in combination with other drugs (2). Econazole nitrate (ECZ) is 1H-imidazole,1-[2-[(4-chlorophenyl) methoxy-]2-(2, 4-dichlorophenyl) [ethyl]-, mononitrate,(±) (1) and is used as an antifungal agent (2; Figure 1 ). A combination of TMC and ECZ is topically administered for the treatment of inflammatory dermatoses, superficial pyodermia, paronychia, diaper dermatitis, dry subchronic dermatoses, and other inflammatory diseases accompanied by fungal infection (3). Two impurities were stated in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), and European Pharmacopoeia (EP; 1, 4, 5): triamcinolone (TMC Imp I) and TMC 21-acetate (TMC Imp II). TMC shows marked instability and undergoes degradation under oxidative, alkali, acid, and photostress conditions, whereas ECZ is considerably stable (6) .
TMC monographs describe HPLC assays (1, 4, 5). Other methods were reported for its determination by micellar electrokinetic chromatography (7) and spectrofluorimetry (8) . TMC was also determined with coformulated drugs by HPLC (9-13) and GC (14) . TMC along with salicylic acid were determined by HPLC (15, 16) and by capillary electrophoresis (17) . On the other hand, several HPLC methods were reported for ECZ determination, either officially (1, 5) or nonofficially (18, 19) . It was also determined among other azole antifungal drugs by UV-spectrophotometry (20) . ECZ and estradiol were determined in human plasma by near-IR spectrometry (21) . Two HPLC methods were found for the determination of TMC and ECZ in binary mixtures (22) and in the presence of their degradation products (23) without any isolation or identification of the degradation products. However, no method was found for the determination of the studied compounds in the presence of TMC impurities. A literature survey revealed that there is no stability-indicating TLC method for TMC and ECZ.
So, our work aimed primarily to prepare, isolate, and identify oxidative, alkali, acid, and photoinduced degradation products of TMC and, secondarily, to develop and validate stability-indicating methods for the determination of TMC and ECZ in the presence of TMC impurities and degradation products. 
Experimental

Apparatus
Samples
(a) Pure samples.-TMC, ECZ, and TMC Imps I and II were kindly supplied by Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany). Their purities were confirmed to be 99.87, 99.92, 99.76, and 99.90%, respectively, according to the USP (1).
(b) Market samples.-Pevisone Cream, manufactured by MINAPHARMA Egypt under license of Janssen CILAGSwitzerland (Batch No. EEE 1787), was labeled to contain 0.1 g TMC and 1.0 g ECZ per 100 g cream and was obtained from a local market.
Chemicals and Solvents
All chemicals used were of analytical grade and solvents were of HPLC grade. Methanol, acetonitrile, ethyl acetate, tetrahydrofuran, formic acid, and H 2 O 2 (30%) were obtained from Lab-Scan Analytical Science (Dublin, Ireland). Potassium dihydrogen phosphate was obtained from Riedel-de Häen (Seelze, Germany). Sodium hydroxide (NaOH), hydrochloric acid (HCl), ammonia solution, and phosphoric acid were obtained from El-Nasr Pharmaceutical and Chemical Co. (Abu-Zaabal, Cairo, Egypt).
(a) Preparation, isolation, and structural elucidation of degradation products.-(1) Preparation of degradation product stock solutions.-(i) Preparation of the oxidative degradation product of TMC.-To accurately weighed 50.00 mg pure TMC, 5 mL 30% H 2 O 2 was added, mixed, and diluted to a 50 mL volume with methanol and refluxed at 90°C for 6 h. The solution was evaporated to near-dryness in a water bath; the residue was dissolved in methanol, cooled, transferred to a 50 mL volumetric flask, and diluted to volume with methanol.
(ii) Preparation of the alkali-induced degradation product of TMC.-Accurately weighed 50.00 mg pure TMC was dissolved in 50 mL NaOH (1 M methanolic solution) and refluxed for 4 h in water bath. The solution was cooled, neutralized, and filtered. The filtrate was evaporated to near-dryness; the residue was dissolved in methanol, transferred to a 50 mL volumetric flask, and diluted to volume with methanol.
(iii) Preparation of the acid-induced degradation product of TMC.-Accurately weighed 50.00 mg pure TMC was dissolved in 50 mL HCl (1 M methanolic solution), refluxed for 8 h, and then neutralized, filtered, and evaporated to dryness. The residue was dissolved in methanol, transferred to a 50 mL volumetric flask, and diluted to volume with methanol.
(iv) Preparation of the photodegradation product of TMC.-Accurately weighed 50.00 mg pure TMC was diluted in a 50 mL methanol solution, transferred to a 50 mL volumetric flask, and diluted to volume with methanol. The solution was subjected to a UV light source at 254 nm for 24 h.
( 2) Isolation of the prepared degradation product.-Prepared stock solutions under different stress conditions (equivalent to 1.00 mg/mL TMC) were applied in the form of bands onto precoated TLC glass plates and allowed to develop in a chromatographic tank previously saturated with a developing system of ethyl acetate-tetrahydrofuran-ammonia (10.0 + 7.0 + 0.1, v/v/v) at ambient temperature. The developed bands were air-dried, scratched, and mixed with methanol; sonicated for 30 min; filtered; and then air-dried.
(3) Identification and structural elucidation of the prepared degradation product.-The dried pure degradation products were dissolved in methanol and subjected to identification and structural elucidation by an LC-MS/MS method at 25°C using an Acquity UPLC BEH shield RP 18 column (2.1 × 150 mm, 1.7 µm) and an acetonitrile-0.1% formic acid mobile phase (35 + (b) Triamcinolone acetonide impurity solutions.-(1) Stock standard solutions of TMC impurities (1.00 mg/mL).-Accurately weighed 25.00 mg each of TMC impurities, Imps I and II, were separately transferred into two separate 25 mL volumetric flasks, dissolved, and diluted with methanol.
(2) Working standard solution I of TMC impurities (0.10 mg/mL).-Prepared by the appropriate and separate dilution of TMC Imps I and II stock standard solutions in methanol or mobile phase for the HPTLC and HPLC methods, respectively.
(3) Working standard solution II of TMC impurities (0.01 mg/mL).-Used for HPLC only and prepared by the appropriate and separate dilution of working standard solution I of TMC Imps I and II.
(c) Triamcinolone acetonide degradation product solutions.-(1) Stock solutions of degradation products (equivalent to 1.00 mg/mL TMC).-Separately prepared as previously described in the Preparation, isolation, and structural elucidation of degradation products section.
(2) Working solution I of TMC oxidative, alkali, acid, or photodegradation products (equivalent to 0.10 mg/mL TMC).-Prepared by the appropriate and separate dilution of the degradation product stock solutions of TMC in methanol or mobile phase for the HPTLC and HPLC methods, respectively.
(3) Working solution II of TMC oxidative, alkali, acid, or photodegradation products (equivalent to 0.01 mg/mL TMC).-Used for HPLC and prepared by the appropriate and separate dilution of working solution I of TMC degradation products.
(d) Econazole nitrate standard solutions.-(1) Stock standard solution of ECZ (1.00 mg/mL).-Prepared in methanol.
(2) Working standard solution of ECZ (0.10 mg/mL).-Prepared by the appropriate dilution of stock standard solution of ECZ in methanol or mobile phase for the HPTLC and HPLC methods, respectively.
(e) Laboratory-prepared mixture solutions.-(1) HPTLC method.-Aliquots of TMC and ECZ stock solutions (1.00 mg/mL), working standard solution I of TMC (0.10 mg/mL), and working standard solution of ECZ (0.10 mg/ mL) were accurately transferred into a series of 10 mL volumetric flasks. To these solutions aliquots of TMC impurity stock and working solutions were added in order to prepare mixtures containing from 10 to 90% impurities; each flask was diluted to volume with methanol. The laboratory-prepared mixtures of the degradation products were prepared in the same manner.
( 2) HPLC method.-Aliquots of working standard solution I of TMC (0.10 mg/mL), working standard solution II of TMC (0.01 mg/mL), and working standard solution of ECZ (0.10 mg/ mL) were transferred into a series of 10 mL volumetric flasks to which aliquots of TMC impurity sample solutions were added to prepare different mixtures of impurities containing 10-90% impurities. Each solution was diluted to volume with mobile phase. The laboratory-prepared mixtures of the degradation products were prepared in the same manner.
(f ) Pharmaceutical formulation solution.-Ten grams of Pevisone Cream (labeled to contain 0.1 g TMC and 1 g ECZ per 100 g cream) were accurately weighed, warmed in a water bath, and sonicated for 30 min after addition of 80 mL methanol. The solution was filtered and transferred into a 100 mL volumetric flask and diluted to volume with methanol to reach a final concentration of 0.10 and 1.00 mg/mL TMC and ECZ, respectively. plates (60 F 254 , 0.20 mm thickness), which were prewashed with methanol and activated at 100°C for 5 min before use. The samples were applied in bands (6 mm in length, 4 mm away from each other, and 15 mm away from the lower edge of the plate). Linear ascending development was allowed in a chromatographic tank previously saturated with an ethyl acetate-tetrahydrofuran-ammonia developing system (10.0 + 7.0 + 0.1, v/v/v) at ambient temperature. The developed plates were then air-dried and scanned at 225 nm.
(2) HPLC method.-A Thermo Hypersil BDS C 18 column (250 × 4 mm, 5.0 µm) was used at ambient temperature with an acetonitrile-methanol-0.05 M potassium dihydrogen phosphate mobile phase adjusted to pH 3.0 with orthophosphoric acid (25 + 15 + 60, v/v/v). The mobile phase was filtered through a 0.45 µm Millipore membrane filter (Billerica, MA) and delivered at a flow rate of 1.5 mL/min. The injection volume was 20.0 µL and detection was at 225 nm. (b) Construction of calibration curves.-(1) HPTLC method.-(i) TMC.-Aliquots of 10.00-28.00 and 2.00-50.00 µL TMC stock standard solution (1.00 mg/mL) and working standard solution I (0.10 mg/mL), respectively, were accurately and separately transferred into 10 mL measuring flasks.
(ii) ECZ.-Aliquots of 5.00-55.00 and 10.00-50.00 µL stock standard solution of ECZ (1.00 mg/mL) and working standard solution of ECZ (0.10 mg/mL), respectively, were separately and accurately transferred into a series of 10 mL measuring flasks.
Both series were diluted to volume with methanol and applied in triplicate onto the HPTLC plates and subsequently chromatographed and scanned. The calibration curves relating the integrated peak area to the corresponding concentrations of TMC and ECZ as µg/band were respectively constructed.
(2) HPLC method.-(i) TMC.-Accurately measured aliquots of TMC working standard solutions I (0.10 mg/mL) and II (0.01 mg/mL) were further diluted to 10 mL with mobile phase to obtain solutions in the range of 0.05-30.00 µg/mL.
(ii) ECZ.-Accurately measured aliquots of ECZ working standard solution (0.10 mg/mL) were further diluted to 10 mL with mobile phase to obtain dilutions in the range of 1.00-40.00 µg/mL.
Each solution was injected in triplicate and chromatographed. The integrated peak areas were plotted against the corresponding concentrations, and the curves were constructed.
(c) Application to laboratory-prepared mixtures and the pharmaceutical formulation.-The laboratory-prepared mixture solutions previously mentioned in the Solutions section were analyzed using the chromatographic conditions mentioned above.
Results and Discussion
An ideal stability-indicating method is the one that quantifies the intact drug and also resolves its possible degradation products (24) . TMC and ECZ are coformulated drugs; for their QC, an efficient method has to be developed and applied not only to quantify the drugs, but also to detect and identify any impurities or degradation products that may be present. Official impurities have to be tested in both raw materials and finished product samples. Moreover, for successful stability studies, assay methods for the determination of drug in the presence of its possible degradation products are needed. The routine HPLC assay of expired batches of a TMC and ECZ formulation just after 1 week of the expiry TMC has two reported impurities, triamcinolone (Imp I) and TMC 21-acetate (Imp II), which should not exceed certain limits due to variable pharmacological effect strengths (25, 26) . TMC Imps I and II are considered process impurities according to the USP (1), BP (4), and EP (5). Moreover, TMC was found to be unstable under different conditions, yielding a TMC oxidative degradation product (TMC Deg. I), TMC alkali degradation product (TMC Deg. II), and TMC acid degradation products (TMC Degs. III, IV, V, and VI; Figure 2 ; 27). However, TMC undergoes partial photodegradation, also producing TMC Degs. II, III, and IV.
ECZ was found to be stable under the previously mentioned stress conditions (6) . Benzoic acid and butylated hydroxyanisole were found in the dosage form and showed marked stability (28) . One HPLC method was reported for the stability study of TMC and ECZ along with benzoic acid and butylated hydroxyanisole under different stress conditions using gradient elution and changing the wavelength of analysis (23) .
Partial degradation of TMC was observed upon using 0.1 M HCl, 0.1 M NaOH, 10% H 2 O 2 , or photodegradation for 30 min without heating. For our intent of identifying and separating the degradation products, our experimental trials were seeking their complete degradation. Refluxing for 6 h with (Figure 2) . First, identification of the degradation products was tried using IR-spectrometry, but it failed to differentiate between TMC and its impurities and degradation products, which was attributed to the presence of similar functional groups. To be more specific, MS was used, and the MS spectrum of TMC showed a molecular ion peak at m/z 435. The mass ion peaks at m/z 394 and 477 for TMC Imps I and II, respectively, were identified. The mass ion peaks at m/z 451, 421, 457, 413, 419, and 441 for TMC Degs. I, II, III, IV, V, and VI, respectively, were found, and, accordingly, the suggested structures for the degradation products are shown in Figure 3a -j. For separation of TMC and ECZ along with degradation products and impurities by TLC method, an efficient stationary phase-mobile phase combination is needed. HPTLC plates were chosen as the stationary phase as they are characterized by smaller particles of stationary phase (<10 µm diameters) and have more advantages over TLC, such as higher resolving power per unit distance, faster development times, and reduced solvent consumption. The excipients did not interfere in the analysis of the two due to their high polarity. Numerous developing systems were tried to obtain moderately good resolution between the 10 components. Toluene-chloroform-methanol-ammonia (5.0 + 6.0 + 2.0 + 0.05, v/v/v/v) was found suitable for isolation, but it was preferable to use less toxic and more environmentally friendly (green) solvents and avoid the use of chloroform and toluene for their severe toxicity (33, 34) . The 10 components were completely and efficiently resolved using ethyl acetate-tetrahydrofuran-ammonia (10.0 + 7.0 + 0.1, v/v/ v). Compact bands and sharp symmetrical peaks were obtained with good resolution (Figure 4) . In order to minimize band diffusion, the optimum bandwidth was chosen to be 6 mm and the interspaces between bands 4 mm. Different scanning wavelengths were tested in which scanning at 225 nm was suitable, providing good sensitivity for both TMC and ECZ with a single plate scan; also, the selected wavelength did not accommodate the excipient, butylated hydroxyanisole (l max = 290 nm). The R f values were 0.77 for TMC; 0.64 and 0.83 for the TMC impurities; 0.05, 0.36, 0.42, 0.46, 0.61, and 0.80 for the TMC degradation products; and 0.56 for ECZ (Figure 4) . The system suitability parameters of the proposed HPTLC method comply with the specifications of the USP (1; Table 1 ).
For the development and optimization of the HPLC method, several trials were carried out to obtain symmetrical resolved peaks. These trials involved the use The ratio of TMC-ECZ in the cream. products were 3.00, 4.71, 8.13, 9.81, 11.03, and 11.78 min, whereas for ECZ, it was 1.90 min. The method succeeded in isolating the 10 components from benzoic acid with suitable resolution ( Figure 5 ). The optimum detection wavelength was 225 nm. System suitability parameters of the proposed HPLC method were calculated, showing good resolution and selectivity and symmetrical peaks ( Table 2) . Validation of the proposed methods was performed according to International Conference on Harmonization guidelines (24) . Table 3 shows the results of accuracy, repeatability, and intermediate precision of the methods. The HPTLC method was valid and applicable for the determination of TMC and ECZ, with mean recoveries of 99.50 ± 1.45 and 99.33 ± 1.75%, respectively, in their pure form. TMC and ECZ were accurately determined by the proposed HPLC method, achieving mean recoveries of 100.09 ± 0.76 and 100.73 ± 1.58% in their pure form, respectively. The specificity of the proposed methods was checked by the analysis of the laboratory-prepared mixtures of TMC, ECZ, and TMC impurities or degradation products in different ratios, as presented in Tables 4 and 5 , respectively. The developed methods were applied for the determination of TMC and ECZ in the pharmaceutical formulation. Satisfactory results were obtained, in good agreement with the label claims ( Table 6 ). The validity of the proposed methods was assessed by applying the standard addition technique, which showed accurate results, and there was no interference from excipients, as shown in Table 7 . Statistical comparison of the results of the TMC and ECZ analysis obtained by the proposed methods and the reported HPLC method (23) was also done using Student's t-test and an F-value at a 95% confidence level (Table 8) , and it was clear that there was no significant difference between the proposed methods with regard to accuracy and precision. Reported HPLC method using a C8 column, 0.20% (w/v) phosphoric acid (adjusted to pH 3.00 using an ammonia solution) and methanol. Quantification of ECZ was at 225 nm, whereas quantification of TMC was at 242 nm. The ratio of TMC-ECZ in the cream.
The proposed methods were considered highly efficient in the separation and quantitation of the studied drugs; moreover, the HPLC method is based on isocratic elution, and the reasons given to avoid gradient elution deserve serious reconsideration, especially for those samples that are easily separated isocratically. However, we believe isocratic elution will remain preferable (35) ; good resolution of the cited active drugs without interference of their excipients was also attained. Identification of the six degradation products of TMC and their resolution, along with the two official impurities of TMC, in a short time of analysis was achieved. Plus, the method is more sensitive than the proposed HPTLC method and the reported HPLC method (23) concerning TMC, which is a very unstable drug.
Conclusions
The proposed methods provided simple, sensitive, selective, and accurate methods for the determination of a TMC and ECZ binary mixture in bulk powder and in their pharmaceutical formulation, without any interference from excipients or TMC official impurities or degradation products. The proposed methods were validated and could be used for routine analysis and stability testing in QC laboratories. HPTLC has the advantages of a short run time, large sample capacity, and the use of a minimal volume of solvents. Reported HPLC method using a C8 column, 0.20% (w/v) phosphoric acid (adjusted to pH 3.00 using an ammonia solution) and methanol. Quantification of ECZ was at 225 nm, whereas quantification of TMC was at 242 nm. 
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